Filings show Chinese gene sequencer BGI has paid out millions in legal fees battling Illumina over patents

Financial figures disclosed as supplement to IPO prospectus, in latest sign regulators are wary of waving through companies facing major overseas IP litigation

Get unlimited access to all IAM content